PAP
PRQR icon

Persistent Asset Partners’s ProQR Therapeutics PRQR Stock Holding History

Persistent Asset Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$440K Buy
236,454
+190,387
+413% +$313K 0.13% 126
2026
Q1 		$74.6K Buy
46,067
+913
+2% +$1.5K 0.03% 251
2025
Q4 		$91.2K Buy
45,154
+8,874
+24% +$20.7K 0.04% 274
2025
Q3 		$77.3K Hold
36,280
– – 0.05% 165
2025
Q2 		$74K Sell
36,280
-11,503
-24% -$18.7K 0.05% 134
2025
Q1 		$63.6K Buy
+47,783
New +$102K 0.05% 128

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Persistent Asset Partners's PRQR Position: Q2 2026 in Review

Persistent Asset Partners increased its ProQR Therapeutics (PRQR) stake by 413% in Q2 2026, buying an estimated $313K and bringing the position to 236,454 shares worth $440K. The position accounts for 0.13% of the portfolio, ranked #126.

Persistent Asset Partners first reported a position in PRQR in Q1 2025 and has held it in 6 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Persistent Asset Partners held 236,454 shares of ProQR Therapeutics worth $440K as of Q2 2026.
  • Persistent Asset Partners bought 190,387 ProQR Therapeutics shares in Q2 2026, an estimated $313K.
  • ProQR Therapeutics made up 0.13% of Persistent Asset Partners's portfolio in Q2 2026, its #126 holding.
  • Persistent Asset Partners first reported a position in ProQR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.